awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38222466-2AF0EC38-50CC-463A-A989-5963B7F1E32A
Q38222466-2AF0EC38-50CC-463A-A989-5963B7F1E32A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38222466-2AF0EC38-50CC-463A-A989-5963B7F1E32A
Phase 1 trial design: is 3 + 3 the best?
P2860
Q38222466-2AF0EC38-50CC-463A-A989-5963B7F1E32A
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38222466-2AF0EC38-50CC-463A-A989-5963B7F1E32A
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b27e17d2af956bcc1a8190a8cbf84c2116c50e5c
P2860
Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.